Nivolumab More Effective Than Ipilimumab in Resected High-Risk Melanoma
Dave LevitanJun 5, 2018Extended follow-up from the CheckMate 238 trial confirmed the superior efficacy of nivolumab vs ipilimumab in patients with stage III and IV resected melanoma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: A Source Type: news